sever
acut
respiratori
syndrom
sar
emerg
new
human
infect
south
china
ultim
caus
infect
almost
death
spread
five
contin
along
airlin
rout
date
sar
patient
adult
case
children
less
year
age
overal
mortal
rate
sar
pandem
approxim
mortal
among
elderli
exceed
subsequ
outbreak
report
later
latest
outbreak
china
occur
result
accident
exposur
laboratori
viru
isol
earli
new
coronaviru
sar
corona
viru
sarscov
identifi
etiolog
agent
respons
human
sar
viru
also
determin
zoonot
origin
bat
chines
palm
civet
mammal
serv
natur
reservoir
host
sarscov
envelop
viru
posit
ssrna
genom
encod
replicas
sever
structur
protein
includ
import
spike
protein
bind
host
receptor
elicit
neutral
antibodi
link
protect
immun
sar
outbreak
remain
seriou
global
concern
continu
threat
zoonot
transmiss
human
accident
intent
releas
laboratori
isol
sarscov
classifi
nation
institut
allergi
infecti
diseas
us
nih
nihniaid
categori
c
pathogen
also
includ
yellow
fever
viru
influenza
viru
emerg
pathogen
could
bioengin
mass
dissemin
base
avail
eas
product
dissemin
potenti
high
morbid
mortal
prospect
renew
transmiss
sarscov
human
popul
suggest
urgent
need
prepar
vaccin
emerg
agent
vaccin
protect
highrisk
group
includ
elderli
healthcar
worker
laboratori
personnel
particularli
critic
sever
recent
review
publish
develop
sar
vaccin
includ
target
sarscov
protein
author
provid
rational
develop
vaccin
base
elicit
neutral
antibodi
receptorbind
domain
rbd
protein
rbd
build
concept
author
provid
roadmap
develop
manufactur
prototyp
rbd
sar
vaccin
roadmap
includ
use
peerreview
literatur
invit
scientif
commun
follow
progress
develop
new
vaccin
activ
nonprofit
product
develop
partnership
pdp
propos
rbd
sar
vaccin
recombin
proteinbas
vaccin
formul
alum
either
alhydrogel
aluminum
phosphat
togeth
suitabl
synthet
tolllik
receptor
agonist
known
glucopyranosyl
lipid
gla
recombin
protein
compris
amino
acid
kda
polypeptid
correspond
minim
rbd
amino
acid
residu
sarscov
protein
fulllength
sarscov
protein
belong
class
viral
fusion
protein
also
includ
glycoprotein
hiv
hemagglutinin
influenza
viru
protein
fragment
span
polypeptid
minim
rbd
respons
viru
bind
hostcel
receptor
angiotensinconvert
enzym
rbd
contain
multipl
conformationdepend
epitop
induc
strong
neutral
antibodi
respons
tcell
respons
longterm
protect
immun
anim
model
well
potent
crossneutr
antibodi
pseudovirus
express
protein
human
sarscov
strain
isol
civet
zoonot
host
moreov
neutral
activ
sera
convalesc
sar
patient
mediat
rbdsspecif
antibodi
rbd
absorb
remov
major
neutral
antibodi
antisera
rabbit
mice
monkey
immun
inactiv
sarscov
modifi
vaccinia
viru
express
protein
studi
provid
rational
select
rbd
import
target
vaccin
develop
recombin
kda
rbd
express
yeast
pichia
pastori
bacteria
escherichia
coli
baculoviru
pend
studi
demonstr
optim
protect
describ
recent
second
rbd
construct
correspond
residu
express
chines
hamster
cell
shown
exhibit
correct
fold
conform
follow
equival
enhanc
protect
construct
also
evalu
backup
vaccin
strategi
gla
kda
synthet
agonist
function
equival
monophosphoryl
lipid
nontox
deriv
lipopolysaccharid
studi
mice
commerci
kill
influenza
vaccin
chemic
synthes
gla
effect
enhanc
titer
oilwat
emuls
squalen
oil
surfact
aqueou
formul
subsequ
studi
reveal
gla
also
enhanc
tcell
respons
influenza
vaccin
among
older
adult
would
desir
featur
sar
vaccin
vaccin
initi
indic
adult
individu
age
consid
greatest
risk
mortal
sar
vaccin
would
administ
inject
product
protect
lethal
sarscov
infect
either
singl
dose
two
dose
space
close
togeth
within
week
vulner
popul
could
rapidli
immun
outbreak
set
tabl
propos
target
product
profil
also
account
stabil
rbd
sar
vaccin
year
allow
emerg
stock
pile
protect
lowcost
atrisk
popul
develop
develop
countri
particularli
southeast
asia
risk
reemerg
greatest
well
develop
countri
sever
differ
technolog
propos
develop
human
sarscov
vaccin
includ
inactiv
viru
vaccin
liveattenu
vaccin
adenoviru
poxviru
vector
vaccin
dna
vaccin
among
concern
regard
vaccin
possibl
vaccin
enhanc
diseas
note
felin
cov
caus
felin
infecti
periton
similarli
laboratori
anim
administ
alumadjuv
wholeviru
sarscov
vaccin
subsequ
challeng
infecti
viru
experienc
enhanc
diseas
immunopatholog
compris
eosiniophil
infiltr
inflammatori
alveolar
damag
similar
immunopatholog
lung
reaction
found
infant
anim
challeng
respiratori
syncyti
viru
rsv
doubleinactiv
sarscov
formalin
ultraviolet
radiat
also
shown
elicit
eosinophil
immunoenhanc
patholog
well
poor
protect
especi
age
anim
suggest
possibl
age
human
desir
target
popul
vaccin
may
particularli
vulner
vaccineinduc
effect
studi
show
venezuelan
equin
enceph
vector
contain
sar
nucleocapsid
np
gene
also
elicit
eosinophil
immunopatholog
balbc
mice
challeng
without
notic
protect
thu
hypothes
np
antigen
sarscov
may
respons
properti
inactiv
vaccin
also
report
formalininactiv
rsv
vaccin
associ
lack
antibodi
affin
matur
follow
poor
tlr
stimul
suggest
np
may
account
entir
immun
enhanc
venezuelan
equin
enceph
vector
contain
sexpress
plasmid
alumadjuv
recombin
protein
express
baculoviru
shown
elicit
protect
balbc
mice
challeng
live
sarscov
howev
remain
unclear
whether
protein
construct
special
report
also
elicit
eosinophil
patholog
one
report
exampl
indic
protein
administ
either
baculovirusexpress
purifi
recombin
protein
viruslik
particl
caus
patholog
eosinophil
albeit
reduc
compar
whole
viru
np
protein
construct
similarli
sar
vaccin
candid
base
recombin
properli
fold
nativ
fulllength
protein
trimer
express
mammalian
cell
also
shown
elicit
immun
enhanc
thu
recombin
protein
elicit
protect
use
human
vaccin
might
limit
host
immunopatholog
order
reengin
protein
safe
effect
vaccin
earli
studi
indic
rbd
compon
highli
protect
laboratori
anim
significantli
reduc
risk
antibodi
enhanc
diseas
addit
data
confirm
sera
sar
convalesc
patient
contain
robust
neutral
antibodi
rbd
summar
vaccin
technolog
potenti
advantag
exist
vaccin
technolog
previous
report
rbd
subunit
vaccin
expect
safer
sar
vaccin
describ
latter
may
elicit
eosinophil
immunopatholog
antibodymedi
enhanc
diseas
vaccin
expect
caus
harm
immun
respons
rbd
subunit
vaccin
may
induc
potent
crossneutr
antibodi
respons
sar
vaccin
report
goal
deliver
produc
formul
recombin
rbd
vaccin
current
good
manufactur
practic
cgmp
prepar
clinic
test
assess
safeti
immuno
genic
efficaci
human
sarscov
infect
key
technolog
object
involv
develop
process
vaccin
manufactur
util
bacteri
yeast
baculoviru
express
system
well
inexpens
purif
method
maxim
product
rbd
antigen
compon
vaccin
minimum
cost
activ
would
take
place
consortium
led
sabin
vaccin
institut
texa
children
hospit
center
vaccin
develop
sabintch
establish
pdp
decadelong
track
record
transit
recombin
protein
vaccin
process
develop
cgmp
clinic
test
pdp
nonprofit
organ
use
industri
practic
often
partner
forprofit
organ
includ
biotechnolog
multin
pharmaceut
compani
well
academ
partner
develop
rbd
sar
vaccin
sabintch
work
immun
design
corpor
seattl
wa
usa
adjuv
access
formul
lindsley
f
kimbal
research
institut
new
york
blood
center
new
york
ny
usa
univers
texa
medic
branch
galveston
tx
usa
area
assay
develop
confirmatori
preclin
efficaci
test
walter
reed
armi
institut
research
wrair
take
lead
final
cgmp
manufactur
figur
batch
product
record
util
ensur
reproduc
vaccin
sever
acut
respiratori
syndrom
special
report
document
qualiti
umbrella
transfer
technolog
wrair
pilot
bioproduct
facil
cgmp
manufactur
final
process
repeat
minimum
three
time
scale
assur
vaccin
manufactur
ferment
formul
reproduc
result
product
suffici
yield
qualiti
addit
antigenadjuv
formul
studi
establish
biochem
immunolog
assess
potenc
perform
minimum
three
full
pilot
run
qualiti
control
process
releas
author
maxim
probabl
success
technolog
transfer
cgmp
manufactur
optim
yield
puriti
acceler
longterm
stabil
studi
conduct
final
formul
chemic
stabil
emphas
provoc
test
high
ph
induc
deamid
select
oxid
agent
produc
oxid
addit
stabil
assess
differ
time
point
conduct
temperatur
incurs
experi
repeat
freezethaw
cycl
storag
differ
temperatur
follow
complet
process
develop
vaccin
product
technolog
transfer
wrair
cgmp
manufactur
final
product
subject
rigor
batteri
assay
lot
product
releas
sabintch
wrair
contractor
tabl
follow
glp
toxicolog
test
regulatori
file
clinic
test
submit
us
fda
major
innov
product
includ
produc
rbd
polypeptid
formul
rather
complet
protein
use
gla
novel
agonist
point
inject
order
limit
vaccineinduc
immunopatholog
enhanc
longterm
stabil
vaccin
maxim
evalu
biochem
biophys
characterist
activ
essenti
vaccin
might
requir
emerg
stockpil
biophys
assess
initi
evalu
recombin
protein
use
multipl
biophys
techniqu
includ
circular
dichroism
intrins
extrins
fluoresc
light
scatter
differenti
scan
calorimetri
collect
studi
provid
specif
inform
concern
physic
state
protein
function
temperatur
ph
biophys
data
use
design
highthroughput
screen
assay
identif
potenti
stabil
typic
gra
gener
regard
safe
design
excipi
stabil
would
accept
fda
regulatori
agenc
preclin
test
innov
human
angiotensinconvert
enzym
transgen
tg
mous
model
follow
tabl
assay
propos
product
character
releas
sehplc
bulk
protein
inprocess
releas
stabil
sehplc
assay
use
analyz
recombin
protein
sampl
crude
ferment
supernat
releas
purifi
bulk
assay
develop
antigen
adapt
rbd
protein
quantit
target
protein
contamin
inprocess
analysi
assay
also
serv
puriti
assay
rbd
protein
rphplc
bulk
protein
releas
stabil
column
condit
screen
varieti
rphplc
column
includ
silicaand
polymerbas
initi
provid
assay
better
resolv
fulllength
rbd
protein
productderiv
cleav
form
ie
kda
differ
multiangl
light
scatter
bulk
protein
inform
multiangl
light
scatter
detector
util
onlin
sehplc
offlin
batch
provid
valuabl
data
regard
aggreg
nativ
state
candid
antigen
solut
assay
could
use
detect
polydispers
rbd
protein
assist
develop
stabl
formul
sdspage
bulk
protein
formul
inprocess
releas
stabil
sdspage
assay
nonreduc
reduc
condit
allow
determin
molecular
weight
aggreg
puriti
sampl
calibr
scan
densitomet
allow
rel
quantit
aspect
assay
involv
determin
limit
detect
linear
rang
assay
assess
puriti
rel
quantiti
assay
alreadi
adapt
implement
routin
rbd
protein
analysi
ntermin
sequenc
bulk
protein
inform
ntermin
sequenc
complet
major
minor
contamin
band
identifi
whether
contamin
product
deriv
cleavag
site
sdspage
complet
transfer
pvdf
membran
sent
contract
servic
audit
sabin
qualiti
assur
team
subject
qualiti
agreement
mass
spectrometri
bulk
protein
inform
esm
carri
micromass
qtof
mass
spectromet
sampl
monitor
mass
posttransl
modif
assay
use
rbd
protein
opa
formul
releas
stabil
opa
assay
measur
protein
content
fluoresc
detect
primari
amin
use
opa
highli
sensit
aminereact
reagent
techniqu
especi
applic
vaccin
formul
alhydrogel
brenntag
biosector
frederikssund
denmark
protein
content
measur
absorb
nm
measur
percentag
alhydrogelbound
protein
alhydrogelunbound
protein
desir
assay
adapt
rbd
protein
formul
buffer
wide
use
determin
alhydrogel
protein
bind
effici
thu
far
hcp
content
inprocess
releas
residu
hcp
impur
inprocess
ferment
purif
product
final
purifi
protein
sampl
evalu
use
slot
blot
system
scan
calibr
densitomet
picogram
level
sensit
vaccin
sever
acut
respiratori
syndrom
intranas
infect
tg
mice
sarscov
weight
loss
clinic
manifest
becom
appar
reach
mortal
within
day
postinfect
contrast
infect
transgeneneg
tg
mice
surviv
without
show
clinic
ill
sever
diseas
develop
tg
mice
make
valuabl
preclin
test
sarscov
vaccin
develop
process
highyield
lowcost
express
purif
recombin
rbd
protein
antigen
follow
formul
alum
presenc
gla
develop
qualif
productspecif
assay
follow
process
formul
optim
incorpor
biophys
profil
complet
three
process
develop
releas
pilot
run
qualiti
control
technolog
transfer
cgmp
manufactur
drug
substanc
product
formal
releas
drug
product
base
qualifi
assay
establish
formal
stabil
program
includ
vaccin
potenc
preind
meet
follow
complet
glp
toxicolog
studi
ind
submiss
approv
clinic
test
first
major
deliver
rbd
proteinbas
sar
vaccin
approv
phase
clinic
test
fda
major
product
challeng
includ
select
antigen
express
system
demonstr
feasibl
scaleup
express
process
develop
accept
yield
puriti
stabil
preclin
optim
test
immunolog
respons
efficaci
laboratori
anim
technolog
transfer
cgmp
manufactur
complet
glp
toxicolog
studi
clinic
develop
plan
meet
requir
fda
anim
rule
immun
correl
protect
three
protein
express
system
bacteri
e
coli
yeast
p
pastori
baculoviru
possibl
mammalian
cell
evalu
parallel
feasibl
scalabl
express
recombin
rbd
protein
preliminari
studi
shown
e
coliexpress
rbd
protein
abl
elicit
high
level
neutral
antibodi
protect
anim
model
howev
e
coliexpress
protein
evalu
formal
character
scalabl
henc
formal
evalu
propos
altern
sabintch
demonstr
p
pastori
robust
sometim
simpler
system
express
sabin
human
hookworm
vaccin
initi
least
two
hookworm
vaccin
antigen
alreadi
shown
suitabl
scalabl
produc
high
resolut
crystal
xray
diffract
well
antigen
suitabl
clinic
develop
rbd
optim
express
system
select
subsequ
studi
base
follow
criteria
yield
scalabl
puriti
stabil
profil
rbd
protein
express
recognit
rbd
conform
monoclon
antibodi
human
convalesc
sera
abil
rbd
inhibit
viral
infect
vitro
abil
rbd
induc
neutral
antibodi
protect
immun
respons
vaccin
mice
subsequ
lethal
challeng
homolog
heterogen
strain
sarscov
use
rbd
protein
select
express
system
adjuv
formul
author
optim
immun
regimen
induc
highest
level
immun
respons
particularli
neutral
antibodi
protect
subsequ
challeng
immunolog
protect
studi
use
wildtyp
tg
mice
requir
optim
term
antigen
dose
formul
number
interv
immun
rout
administr
evalu
efficaci
optim
regimen
extend
studi
optim
longterm
immunolog
respons
length
protect
vaccineinduc
immunopatholog
follow
select
express
system
research
cell
bank
gener
express
rbd
bio
reactor
ferment
optim
improv
yield
puriti
stabil
activ
solubl
protein
optim
growth
induct
condit
ferment
process
determin
first
use
flask
best
paramet
select
evalu
scale
aim
obtain
reproduc
highyield
product
minimum
mgl
target
major
compon
activ
includ
product
rbd
protein
ferment
scale
purif
use
ionexchang
hydrophob
interact
column
chromatographi
document
three
success
process
develop
run
ferment
protein
purif
develop
productspecif
assay
monitor
antigen
ident
puriti
integr
ferment
purif
clinic
lot
releas
develop
buffer
adjuv
formul
product
stabil
studi
process
develop
formul
technolog
select
rbd
vaccin
transfer
wrair
develop
qualifi
assay
use
lot
releas
special
report
stabilitypot
test
proteinspecif
assay
conduct
sabintch
tabl
regul
assay
contract
industri
partner
assay
provid
import
feedback
puriti
stabil
integr
molecul
essenti
guid
process
develop
formul
addit
new
assay
technolog
typic
identifi
implement
appropri
ensur
specif
characterist
molecul
maintain
sever
assay
either
current
use
develop
rbd
protein
qualifi
sabintch
recombin
antigen
phase
clinic
trial
follow
preind
meet
fda
glp
toxicolog
test
perform
sabin
vaccin
institut
serv
sponsor
prepar
ind
vaccin
initi
design
global
access
roadmap
vaccin
uptak
distribut
also
draft
safeti
rbd
vaccin
evalu
phase
clinic
trial
new
subpart
us
code
feder
regul
accept
approv
new
drug
pivot
anim
efficaci
studi
base
anim
rule
human
efficaci
studi
ethic
feasibl
would
deliber
expos
healthi
human
volunt
lethal
agent
safeti
immunogen
studi
rbd
vaccin
feasibl
human
challeng
studi
sarscov
would
consid
safe
ethic
therefor
pivot
anim
efficaci
studi
conduct
use
least
one
anim
model
exhibit
host
pathogen
immun
respons
match
close
possibl
human
besid
nonhuman
primat
model
diseas
lethal
reveal
transgen
mice
infect
clinic
isol
sarscov
eg
urbani
elicit
wildtyp
balbc
mice
respons
mouseadapt
strain
sarscov
design
make
among
best
model
evalu
vivo
efficaci
sar
vaccin
determin
viru
neutral
antibodi
titer
among
vaccin
recipi
pivot
anim
efficaci
studi
import
bridg
anim
protect
data
human
serv
immun
correl
protect
antibodi
titer
would
equal
exceed
neutral
antibodi
titer
amount
found
sera
convalesc
patient
desir
quantiti
specif
neutral
antibodi
determin
consult
expert
clinic
virologist
addit
level
antibodi
affin
avid
may
need
establish
use
surfac
plasmon
reson
technolog
follow
initi
discoveri
sarscov
etiolog
agent
human
sar
intern
effort
underway
develop
test
prototyp
vaccin
intens
studi
determin
deliv
inject
vaccin
inactiv
sarscov
elicit
protect
neutral
antibodi
howev
vaccin
also
caus
immunoenhanc
patholog
bear
resembl
immuno
patholog
derail
effort
produc
inactiv
rsv
vaccin
four
decad
ago
subsequ
effort
determin
protect
neutral
antibodi
direct
primarili
protein
respons
receptorbind
even
vaccin
compris
fulllength
protein
elicit
immunopatholog
albeit
reduc
sar
emerg
new
highli
lethal
human
infect
south
china
sarscov
consid
potenti
bioweapon
threat
vaccin
particularli
critic
protect
highrisk
group
includ
elderli
healthcar
worker
laboratori
personnel
propos
rbd
sar
vaccin
recombin
proteinbas
vaccin
formul
alum
glucopyranosyl
lipid
tolllik
receptor
agonist
novel
adjuv
recombin
protein
compris
amino
acid
kda
polypeptid
correspond
minim
rbd
sarscov
protein
vaccin
initi
indic
adult
individu
age
consid
greatest
risk
mortal
sar
vaccin
would
administ
inject
product
protect
lethal
sarscov
infect
either
singl
dose
two
dose
space
close
togeth
within
week
vulner
popul
could
rapidli
immun
outbreak
set
high
stabil
rbd
sar
vaccin
stockpil
year
emerg
use
unlik
prototyp
vaccin
rbd
sar
vaccin
design
reduc
likelihood
eosinophil
immunopatholog
immedi
goal
includ
develop
process
highyield
lowcost
express
purif
rbd
protein
antigen
follow
formul
alum
use
glucopyranosyl
lipid
point
inject
develop
qualif
productspecif
assay
follow
process
formul
optim
incorpor
biochem
biophys
assess
complet
three
process
develop
pilot
run
qualiti
control
test
technolog
transfer
cgmp
manufactur
process
drug
substanc
drug
product
formal
releas
drug
product
establish
formal
stabil
program
includ
vaccin
potenc
preinvestig
new
drug
meet
follow
complet
good
laboratori
practic
toxicolog
studi
investig
new
drug
submiss
follow
approv
clinic
test
met
object
expect
first
major
deliver
rbd
sar
vaccin
approv
phase
clinic
test
us
fda
vaccin
develop
led
nonprofit
product
develop
partnership
collabor
key
academ
militari
industri
partner
amount
therefor
effort
instead
focus
subunit
vaccin
compris
rbd
essenti
compon
respons
receptor
bind
laboratori
anim
recombin
rbd
subunit
vaccin
elicit
protect
compar
proteinbas
vaccin
minim
immun
enhanc
immuno
patholog
prototyp
recombin
rbd
sar
vaccin
formul
alum
togeth
gla
point
inject
develop
activ
nonprofit
pdp
collabor
key
academ
industri
militari
partner
within
year
anticip
prototyp
recombin
rbd
sar
vaccin
formul
alum
gla
point
inject
complet
cgmp
manufactur
wrair
follow
lot
releas
glp
toxicolog
test
vaccin
readi
ind
submiss
phase
clinic
test
full
clinic
develop
plan
lead
product
licensur
need
outsid
consult
confirm
quantiti
qualiti
well
affin
avid
viru
neutral
antibodi
requir
protect
research
report
public
support
nation
institut
allergi
infecti
diseas
nih
award
number
content
sole
respons
author
necessarili
repres
offici
view
nih
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
write
assist
util
product
manuscript
paper
potenti
glucopyranosyl
lipid
new
synthet
adjuv
